Following iotrolan cervical myelography 14 consecutive patients were evaluated with respect to intracranial contrast distribution and elimination, side effects, EEG-changes and psychometric assessments. The contrast medium is distributed in the subarachnoid space, in the ventricles and finally extracellularly in the cortex. Headache was the most prevalent side effect, occurring in half of the patients, 43% of “severe” grade. Eight patients showed mild nonspecific EEG-changes and all patients showed neuropsychologic disturbances.
CoutinhoC.McGeorgeA.MacPhersonP.TeasdaleE.: Iotrolan versus iopamidol for radiculography. A randomized double-blind study. Br. J. Radiol.61 (1988), 89.
2.
CoutinhoC.McGeorgeA.MacPhersonP.TeasdaleE.: Iotrolan versus iopamidol for cervical myelography. A randomized double-blind trial. Br. J. Radiol.61 (1988), 965.
3.
CronqvistS. E.HoltåsS. L.LaikeT.OzolinsA.: Psychic changes following myelography with metrizamide and iohexol. Acta Radiol. Diagnosis25 (1984), 369.
4.
GonsetteR. E.LiesenborghsL.: Iohexol. A new nonionic contrast medium for myelography and cisternography with markedly reduced neurotoxicity. Invest. Radiol. (Suppl.) 20 (1985), 32.
5.
HammerB.DeisenhammerE.: Iotrol, a new water-soluble non-ionic dimeric contrast medium for intrathecal use. Neuroradiology27 (1985), 337.
6.
HindmarshT.: Computer cisternography for evaluation of CSF flow dynamics. Acta Radiol.Suppl. 355 (1977), 269.
7.
HoffmannB.BeckerH.Wenzel-HoraB. I.: Influence of the spread and period of retention of iotrolan in the subarachnoid space on the side effects rate in myelography. Neuroradiology29 (1987), 380.
8.
LambJ. T.: Iohexol vs. iopamidol for myelography. Invest. Radiol.Suppl. 20 (1985), 37.
9.
LambJ.McAllisterV.NelsonM.BartlettR.SmithI.DeopugariC. E.: A prospective comparison of iotrolan, iohexol and iopamidol for lumbar myelography. Acta Radiol.Suppl. 369 (1986), 524.
10.
MacPhersonP.TeasdaleE.McGeorgeA. P.: Direct puncture versus run up cervical myelography with iopamidol. A comparison of side effects, EEG changes and radiographic quality. J. Neurol. Neurosurg. Psychiatry46 (1983), 959.
11.
MadsenH. H. T.OlsenN. K.SvareU.ZeebergI.: Intratekal iohexolfordeling efter cervikal myelografi. (In Danish.). Ugeskr. Læger152 (1990), 2489.
12.
OlsenN. K.MadsenH. H. T.EriksenF. B.SvareU.ZeebergI.: Intracranial iohexol-distribution following cervical myelography, postmyelographic registration of adverse effects, psychometric assessment and electro-encephalographic recording. Acta Neurol. Scand.82 (1990), 321.
13.
RingelK.KlotzE.Wenzel-HoraB. I.: Iotrolan versus iopamidol. A controlled, multicenter, double-blind study of lumbar and direct cervical myelography. In: Recent developments in nonionic contrast media, p. 153. Edited by TaenzerV.WendeS.. Thieme Med. Publ., New York1989.
14.
ShawD. D.Bach-GansmoT.DahlstromK.: Iohexol. Summary of North American and European clinical trials in adult lumbar, thoracic and cervical myelography with a new nonionic contrast medium. Invest. Radiol.Suppl. 20 (1985), 44.
15.
ValkJ.CrezeeF. C.de SlegteR. G. M.HazenbergG. J.WolbersJ.Bach-GansmoT.: Iohexol 300 mg I/ml versus iopamidol 300 mg I/ml for cervical myelography double blind trial. Neuroradiology29 (1987), 202.
16.
WeinmannH.-J.VogelsangH.MützelW.SpeckU.: Plasma level and renal excretion of iotrolan after lumbar injection in patients. In: Recent developments in nonionic contrast media, p. 224. Edited by TaenzerV.WendeS.. Thieme Med. Publ., New York1989.
